Martin Dow Limited has been granted an establishment license by the Drug Regulatory Authority of Pakistan (DRAP) to manufacture, fill, re-label, and package clinical chemistry reagents—a major regulatory milestone enabling the company to vertically integrate and strengthen Pakistan’s reliance on domestic biochemical reagents.
Read More: StockIntel.com by Capital Stake Becomes Pakistan’s First Multi‑Broker Trading Platform
An official from Martin Dow said, “This license empowers us to bring more manufacturing control and reliability into our clinical chemistry business. It gives us the foundation to reduce import dependency and offer better supply security to labs nationwide.” The company now expects to launch reagents tailored to local diagnostic needs, offering rapid turnaround, compliance, and cost efficiencies.
Earlier, Martin Dow had entered agreements to supply core reagents to diagnostic labs and hospitals. With the new license, it will be able to perform in-house activities such as reagent formulation, packaging, and labeling—all under regulatory oversight. This capability is expected to foster faster product development cycles and quality assurance.
Laboratories across Pakistan had long relied on imported reagents with variable delivery timelines and foreign currency exposure. Martin Dow noted that local production with DRAP’s authorization will help stabilize import cost volatility, ensure consistent supply, and support the clinical diagnostics sector.
As Martin Dow accelerates reagent commercialization and capacity expansion, it positions itself not just as a pharmaceutical innovator but as a strategic partner to the national healthcare infrastructure—bolstering local capabilities and supporting timely, reliable diagnostic services.
